Evidence map›Paper›PMID 40422908›Full record

ArticleMetabolites2025

Urine Metabolomic Profiling and Machine Learning in Autism Spectrum Disorder Diagnosis: Toward Precision Treatment.

Shula Shazman, Julie Carmel, Maxim Itkin, Sergey Malitsky, Monia Shalan, Eyal Soreq, Evan Elliott, Maya Lebow, Yael Kuperman

Abstract read
In one paragraph

Article in Metabolites, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shula ShazmanDepartment of Mathematics and Computer Science, The Open University of Israel, Raanana 4353701, Israel.ORCID 0000-0001-9350-7676
Julie CarmelAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Maxim ItkinMetabolic Profiling Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-1348-2814
Sergey MalitskyMetabolic Profiling Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-4619-7219
Monia ShalanZiv Medical Center, Safed 1311502, Israel.
Eyal SoreqDepartment of Brain Science, Faculty of Medicine, Imperial College London, London SW3 6LY, UK.ORCID 0000-0003-4809-4889
Evan ElliottAzrieli Faculty of Medicine, Bar Ilan University, Safed 1311502, Israel.
Maya LebowANeustart, Ltd., Rishon LeZion 7526088, Israel.
Yael KupermanANeustart, Ltd., Rishon LeZion 7526088, Israel.ORCID 0000-0003-3830-1856

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAutism spectrum disorder (ASD) diagnosis traditionally relies on behavioral assessments, which can be subjective and often lead to delayed identification. Recent advances in metabolomics and machine learning offer promising alternatives for more objective and precise diagnostic approaches.

methodsFirst-morning urine samples were collected from 52 children (32 with ASD and 20 neurotypical controls), aged 5.04 ± 1.87 and 5.50 ± 1.74 years, respectively. Using liquid chromatography-mass spectrometry (LC-MS), 293 metabolites were identified and categorized into 189 endogenous and 104 exogenous metabolites. Various machine learning classifiers (random forest, logistic regression, random tree, and naïve Bayes) were applied to differentiate ASD and control groups through 10-fold cross-validation.

resultsThe random forest classifier achieved 85% accuracy and an area under the curve (AUC) of 0.9 using all 293 metabolites. Classification based solely on endogenous metabolites yielded 85% accuracy and an AUC of 0.86, whereas using exogenous metabolites alone resulted in lower performance (71% accuracy and an AUC of 0.72).

conclusionThis study demonstrates the potential of urine metabolomic profiling, particularly endogenous metabolites, as a complementary diagnostic tool for ASD. The high classification accuracy highlights the feasibility of developing assistive diagnostic methods based on metabolite profiles, although further research is needed to link these profiles to specific behavioral characteristics and ASD subtypes.

Indexed as

autism spectrum disorderdiagnostic biomarkersendogenous metabolitesexposomeliquid chromatography-mass spectrometrymachine learningmachine learning classifiersmetabolomicsrandom foresturine metabolites

Identifiers

PMID40422908
PMCPMC12113876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.